See the DrugPatentWatch profile for Fostamatinib
What is fostamatinib, and what is it used for?
Fostamatinib (brand name Tavalisse) is a prescription medicine that works by inhibiting spleen tyrosine kinase (SYK), a signaling pathway involved in immune and inflammatory processes. It is used to treat adults with immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment [1].
How does fostamatinib work in immune thrombocytopenia (ITP)?
In ITP, the immune system contributes to platelet destruction and impaired platelet production. By blocking SYK, fostamatinib reduces immune-cell signaling that helps drive platelet loss in this condition [1].
Who can take it (and who typically can’t)?
Fostamatinib is indicated for adults with chronic immune thrombocytopenia (ITP) after prior therapy did not work well enough [1]. Patient eligibility depends on individual factors such as comorbidities and concurrent medications, which clinicians assess before starting treatment [1].
What are the common side effects people report?
Across clinical use, fostamatinib can cause side effects related to its effects on immune signaling and on organ systems involved in metabolism and fluid balance. Reported adverse effects include diarrhea, nausea, hypertension, fatigue, and elevated liver enzymes [1].
How is it taken, and does the dose change?
Fostamatinib is taken by mouth. Dosing and any dose adjustments are managed by the treating clinician based on response and tolerability [1].
What should patients watch for during treatment?
Because fostamatinib can affect blood pressure and liver function, monitoring for hypertension and liver enzyme changes is part of routine care in patients taking it [1]. Patients are also advised to seek medical advice promptly if they develop concerning symptoms (for example, severe or persistent diarrhea, significant weakness, or signs of liver problems), since management may require dose modification or additional treatment [1].
How does fostamatinib compare with other ITP treatments?
For adults with ITP after prior therapy, treatment options can include corticosteroids, thrombopoietin receptor agonists, and other immunomodulatory approaches; fostamatinib is a SYK inhibitor option aimed at reducing platelet destruction through a different mechanism [1]. Which therapy fits best depends on medical history, treatment goals, prior responses, and safety considerations.
Is there drug interaction risk with fostamatinib?
As with many oral cancer/immune pathway drugs, interactions can occur through drug-metabolizing enzymes and transporter pathways. Patients should tell clinicians about all medicines, supplements, and over-the-counter products before starting fostamatinib so potential interactions can be assessed [1].
---
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/